ClearPoint Neuro Reports Third Quarter 2026 Results

ClearPoint Neuro, Inc. (CLPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ClearPoint Neuro Reports Third Quarter 2026 Results Neurosurgery Navigation & Therapy Grew 59% to $5.4 Million SOLANA BEACH, CA, October 28, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offerin

Event · Earnings
Also in this documentGuidance · $48M–$50M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 28, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CLPT
Bullish
high confidence
Mentioned
$CLPT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CLPTBullishMed
01

Why it matters

The earnings beat and issued guidance could trigger short‑term buying interest, but investors should watch operating expense growth.

02

Market read

First‑report earnings with strong growth; likely to move CLPT modestly higher.

03

What to watch

Cash burn increased to $13.4M and gross margin fell, which could pressure near‑term profitability.

Relevance 7/10Novelty 8/10Timing: after-hours release
AlphAI · Earnings readCLPT · third quarter 2026 · ended September 30, 2026

ClearPoint Neuro Reports Third Quarter 2026 Results Neurosurgery Navigation & Therapy Grew 59% to $5.4 Million

→Mixed quarter

Revenue growth accelerated to 36%, led by neurosurgery navigation and therapy and capital equipment and software, but gross margin declined, operating expenses increased, and the Company reported a wider net loss.

Revenue
$12.1M
36% y/y
Biologics and drug delivery revenue
$4.9M
11% y/y
Gross margin · GAAP
58%
EPS · GAAP
$ (0.24 )
2026 outlook
$48.0 million and $50.0 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, three months ended September 30, 2026GAAP$12.1M–36%
Product revenue, three months ended September 30, 2026GAAP$7.89M––
Service and other revenue, three months ended September 30, 2026GAAP$4.18M––
Cost of revenue, three months ended September 30, 2026GAAP$5.02M––
Gross profit, three months ended September 30, 2026GAAP$7.06M––
Gross margin, three months ended September 30, 2026GAAP58%––
Research and development costs, three months ended September 30, 2026GAAP$4.02M––
Sales and marketing expenses, three months ended September 30, 2026GAAP$5.53M––
General and administrative expenses, three months ended September 30, 2026GAAP$3.84M––
Operating expenses, three months ended September 30, 2026GAAP$13.4M–23%
Operating loss, three months ended September 30, 2026GAAP−$6.33M––
Other income (expense), net, three months ended September 30, 2026GAAP$22K––
Interest income, three months ended September 30, 2026GAAP$292K––
Interest expense, three months ended September 30, 2026GAAP−$1.45M––
Net loss before income taxes, three months ended September 30, 2026GAAP−$7.46M––
Income tax (benefit) expense, three months ended September 30, 2026GAAP−$4K––
Net loss, three months ended September 30, 2026GAAP−$7.46M––
Net loss per share attributable to common stockholders, basic and diluted, three months ended September 30, 2026GAAP$ (0.24 )––
Weighted average shares outstanding, basic and diluted, three months ended September 30, 2026GAAP30,983,193––
Total revenue, nine months ended September 30, 2026GAAP$35.08M––
Product revenue, nine months ended September 30, 2026GAAP$24.07M––
Service and other revenue, nine months ended September 30, 2026GAAP$11.01M––
Gross profit, nine months ended September 30, 2026GAAP$21.52M––
Operating loss, nine months ended September 30, 2026GAAP−$25.05M––
Net loss, nine months ended September 30, 2026GAAP−$28.35M––
Net loss per share attributable to common stockholders, basic and diluted, nine months ended September 30, 2026GAAP$ (0.94 )––
Net cash used in operating activities, nine months ended September 30, 2026GAAP−$20.09M––
Net cash used in investing activities, nine months ended September 30, 2026GAAP−$996K––
Net cash provided by financing activities, nine months ended September 30, 2026GAAP$21.23M––

Segments

SegmentRevenueq/qy/y
Biologics and drug delivery revenueThe increase is primarily attributable to higher revenue from services performed at ClearPoint Advanced Laboratories.$4.9M–11%
Neurosurgery navigation and therapy revenueThe increase is driven primarily by additional revenues due to sales of the IRRA flow product, which the Company acquired in connection with its acquisition of IRRAS in the fourth quarter of 2025.$5.4M–59%
Capital equipment and software revenueGrowth was primarily due to an increase in placements of ClearPoint navigation capital and software, IRRA flow control units, and Prism laser units.$1.7M–68%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

2026 outlook

  • Revenue$48.0 million and $50.0 million

Capital returns

  • Proceeds from issuance of common stock under at-the-market equity offering program, net of issuance costs of $0.5 million: $ 22,020 (in thousands)

What drove it

  • Total revenue increased $3.2 million, or 36%, driven by growth across biologics and drug delivery, neurosurgery navigation and therapy, and capital equipment and software.
  • Management said revenue growth outpaced operating expense growth of 23% as completion of the IRRA flow product integration enabled improved operating leverage.
  • The Company reported that one partner submitted its first formal BLA for the treatment of Huntington's Disease.
  • ClearPoint is an industry partner in a five-year, $2.98 million competitively awarded NCI R01 led by Dartmouth Health to advance MR-guided laser therapy for spinal metastases.

Concerns

  • Gross margin was 58%, compared with 63% in the same period in 2025, due primarily to overhead costs at the new ClearPoint Advanced Laboratories facility and additional amortization expense of acquired intangible assets.
  • Operating expenses increased 23%, mainly due to the IRRAS acquisition in November 2025, including higher personnel costs, occupancy costs, and travel costs.
  • Net loss was $ (7,460 ) (in thousands), compared with $ (5,891 ) (in thousands) in the same period in 2025.
  • Net cash used in operating activities was $ (20,094 ) (in thousands) for the nine months ended September 30, 2026.
  • Interest expense was $ (1,446 ) (in thousands) for the three months ended September 30, 2026, compared with $ (939 ) (in thousands) in the same period in 2025.

What to watch

  • Execution against 2026 revenue guidance of $48.0 million and $50.0 million.
  • Adoption and growth of neurosurgery navigation and therapy products, including IRRA flow and laser therapy.
  • Growth of biologics and drug delivery business, including preclinical services at ClearPoint Advanced Laboratories.
  • The timing and outcome of biologics and drug delivery partners' clinical trials and regulatory submissions.
  • The integration of acquired businesses, including IRRAS.

Balance sheet and cash flow

  • Cash and cash equivalents were $46.2 million as of September 30, 2026, compared with $45.9 million at December 31, 2025.
  • Long-term notes payable, net: $ 50,840 (in thousands) at September 30, 2026, compared with $ 49,077 (in thousands) at December 31, 2025.
  • Cash, cash equivalents and restricted cash, end of period: $ 47,110 (in thousands) for the nine months ended September 30, 2026, compared with $ 38,401 (in thousands) for the nine months ended September 30, 2025.
  • Purchases of property and equipment: $ (996 ) (in thousands) for the nine months ended September 30, 2026, compared with $ (473 ) (in thousands) for the nine months ended September 30, 2025.
  • Net change in cash, cash equivalents and restricted cash: $ 137 (in thousands) for the nine months ended September 30, 2026, compared with $ 18,297 (in thousands) for the nine months ended September 30, 2025.

Analysis

ClearPoint Neuro reported third-quarter revenue of $12.1 million, up 36% from $8.9 million in the same period in 2025. Revenue growth was broad across the operating categories discussed in the release. Neurosurgery navigation and therapy increased 59% to $5.4 million, biologics and drug delivery increased 11% to $4.9 million, and capital equipment and software increased 68% to a record $1.7 million. The IRRA flow portfolio was a major contributor to navigation and therapy growth, while higher services performed at ClearPoint Advanced Laboratories supported biologics and drug delivery revenue.

The quarter showed improved top-line momentum but weaker gross profitability. Gross margin declined to 58% from 63%, with the Company citing overhead costs at the new ClearPoint Advanced Laboratories facility and additional amortization of acquired intangible assets. Operating expenses increased 23% to $13.4 million, principally reflecting the November 2025 IRRAS acquisition, higher clinical and sales personnel costs, occupancy costs, and travel costs. The result was an operating loss of $ (6,332 ) (in thousands), compared with $ (5,276 ) (in thousands) in the prior-year quarter, and a net loss of $ (7,460 ) (in thousands), compared with $ (5,891 ) (in thousands).

Liquidity was supported by equity financing. Cash and cash equivalents were $46.2 million at September 30, 2026, compared with $45.9 million at December 31, 2025. The Company received net proceeds of $22.0 million from its at-the-market equity offering program, which partly offset $ (20,094 ) (in thousands) of net cash used in operating activities during the first nine months of 2026. Long-term notes payable, net, were $ 50,840 (in thousands) at September 30, 2026.

The Company now estimates 2026 revenue of between $48.0 million and $50.0 million. Investors will be focused on whether continued IRRA flow sales, capital placements, and ClearPoint Advanced Laboratories services can sustain revenue growth while the Company works to improve the 58% gross margin and contain operating cash use. Other reported operational developments include a first formal BLA submitted by one partner for Huntington's Disease and ClearPoint's participation in a five-year, $2.98 million NCI R01 supporting MR-guided laser therapy for spinal metastases.

Management, verbatim

Throughout 2026 we have continued to make substantial strategic progress in building our comprehensive drug delivery ecosystem, adding new biopharma partners, and assisting existing partners progress through the regulatory process globally.

Joe Burnett, President and CEO at ClearPoint Neuro

The acceleration of our financial performance in the third quarter was driven by our core organic clinical product revenue, as well as our biologics and drug delivery revenue both returning to double-digit growth.

Joe Burnett, President and CEO at ClearPoint Neuro

The 36% revenue growth outpaced operating expense growth of 23% in the third quarter, as the completion of the IRRA flow product integration has enabled improved operating leverage.

Joe Burnett, President and CEO at ClearPoint Neuro

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for reported quarterly metrics
  • Quarterly operating cash flow
  • Free cash flow
  • Share repurchases
  • Dividends
  • Non-GAAP financial measures
  • Gross margin guidance
  • Operating expense guidance
  • Tax-rate guidance
  • Previous-release outlook needed to assess actual results versus prior guidance

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

ClearPoint Neuro is a Nasdaq‑listed developer of navigation and drug‑delivery systems for neurosurgery.

Company-level read

Ticker impact

$CLPTBullishHigh confidence
Context

ClearPoint Neuro disclosed Q3 2026 results with 36% revenue growth and issued guidance to $48‑$50M.

Expected impact

likely upward pressure as investors price in issued revenue guidance

Evidence & confidence

Revenue jumped 36% YoY, neurosurgery navigation sales rose 59%, and the company issued guidance above prior expectations, indicating improved fundamentals.

Market effects

Boosts outlook for med‑tech and neuro‑navigation sector as growth accelerates.

Positive for US biotech/medical device investors.

Limited to niche medical‑device space; no broad market effect.

Counterpoint

Growth may be unsustainable if IRRA flow integration costs rise.

Key entities

  • Joe Burnett

    President and CEO of ClearPoint Neuro

Every CLPT earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$CLPTMed

ClearPoint Neuro (CLPT) Q3 2026 Earnings Call Transcript

ClearPoint Neuro (CLPT) reported Q3 2026 revenue of $12.1M, up 36% YoY, driven by growth in neurosurgery navigation and capital equipment sales. The company used its ATM facility to raise $22M, ending the quarter with $46.2M in cash. CLPT supports uniQure's BLA submission for Huntington's disease treatment, aiming for parallel FDA approvals. The company is preparing for increased Phase III trials and commercial product launches in 2027.

$CLPTMed

What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call

ClearPoint Neuro (CLPT) reported Q3 operating expenses of $13.4M, down from $17M in Q2. Cash reserves were $46.2M, with $22M raised via equity offering. CEO Burnett expects reduced operating burn and capital expenditures. The company awaits FDA decision on AMT-130 submission, with potential parallel approvals for drug and device. ClearPoint outlined four growth pillars, including biologics, neurosurgery navigation, and laser therapy.

$CLPTHighAI 8/10

ClearPoint Neuro stock tumbles on uniQure trial setback

ClearPoint Neuro (CLPT) shares dropped 24% after partner uniQure (QURE) reported disappointing trial data for its Huntington's disease treatment, AMT-130. The therapy failed to meet primary clinical measures, raising concerns about future revenue for ClearPoint Neuro, which provides delivery hardware and software for the treatment.